LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (OTCBB: NMRD), a medical device company announced the latest version of the sensor component of its sugarBEAT® non-invasive wireless skin-patch has achieved a more than 300% improvement in glucose detection.
This major improvement is expected to enhance sugarBEAT® accuracy as expressed through MARD, by enabling diabetics to better detect small fluctuations in glucose levels, and for sugarBEAT® to detect glucose at very low levels.
The sugarBEAT® clinical trial program, involving up to 75 patients over 525 days, is due to commence shortly, with product launch anticipated before the end of 2017 in the UK.
The needle-free and daily-disposable format of the sugarBEAT® skin-patch is expected to provide a non-invasive and flexible way for diabetics to better manage their glucose levels.
SugarBEAT’s® cost-effective design, consisting of a reusable Bluetooth-enabled body-worn transmitter containing a low-cost disposable adhesive skin-patch will make glucose monitoring more affordable, especially for non-insulin-injecting diabetics.
Alongside the sugarBEAT® wireless skin-patch, Nemaura has also successfully developed and tested the associated sugarBEAT® mobile phone application.
This Medical-grade App connects by Bluetooth to the skin-patch and displays glucose readings on a continuous basis as well as providing summary Ambulatory Glucose Profile (AGP) trends.
The App also allows for additional manual lifestyle inputs helping diabetics to better understand and manage their condition.
About Nemaura Medical, Inc.
Nemaura Medical is developing the daily-disposable wireless sugarBEAT® adhesive skin-patch as a non-invasive, needle-free, pain-free and affordable continuous glucose monitoring (CGM) system for adjunctive use by diabetics. Further opportunity may exist in intensive-care hospital settings, where continuous glucose monitoring is critical.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura Medical’s ongoing studies, including the safety and efficacy of Nemaura Medical’s sugarBEAT® CGM system, the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell sugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to sugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the current year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.